Fjarde Ap Fonden Novo Cure LTD Transaction History

Fjarde Ap Fonden

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$11.13 - $15.78 $64,554 - $91,524	5,800 Added 68.35%	14,286 $213,000
Q3 2023 Oct 23, 2023	SELL	$16.15 - $42.35 $240,861 - $631,607	-14,914 Reduced 63.74%	8,486 $137,000
Q4 2022 Feb 14, 2023	BUY	$63.98 - $85.37 $19,194 - $25,611	300 Added 1.3%	23,400 $1.72 Million
Q2 2022 Aug 11, 2022	SELL	$56.6 - $89.9 $526,380 - $836,070	-9,300 Reduced 28.7%	23,100 $1.61 Million
Q1 2022 May 13, 2022	SELL	$60.15 - $84.52 $288,720 - $405,696	-4,800 Reduced 12.9%	32,400 $2.68 Million
Q4 2021 Feb 15, 2022	BUY	$75.08 - $121.99 $2.79 Million - $4.54 Million	37,200 New	37,200 $2.79 Million

290

75.6M

1.77M

538K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $2.16B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Fjarde Ap Fonden , based on Form 13F filings with the SEC.

Stay updated on Fjarde Ap Fonden with notifications on news.